Atossa Therapeutics' (ATOS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reissued their buy rating on shares of Atossa Therapeutics (NASDAQ:ATOS - Free Report) in a research note released on Thursday morning,Benzinga reports. The brokerage currently has a $7.00 price objective on the stock.

A number of other analysts have also commented on ATOS. Ascendiant Capital Markets upped their price objective on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a "buy" rating in a research note on Monday, December 9th. StockNews.com lowered shares of Atossa Therapeutics from a "hold" rating to a "sell" rating in a research note on Monday, November 18th.

Atossa Therapeutics Stock Performance

Shares of ATOS traded down $0.02 during midday trading on Thursday, hitting $0.84. 721,103 shares of the stock traded hands, compared to its average volume of 819,255. The business's 50 day moving average price is $1.03 and its two-hundred day moving average price is $1.27. Atossa Therapeutics has a 1-year low of $0.72 and a 1-year high of $2.31. The firm has a market capitalization of $105.91 million, a PE ratio of -3.83 and a beta of 1.26.

Hedge Funds Weigh In On Atossa Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ATOS. Barclays PLC increased its stake in shares of Atossa Therapeutics by 280.9% in the third quarter. Barclays PLC now owns 167,718 shares of the company's stock worth $255,000 after acquiring an additional 123,683 shares during the last quarter. State Street Corp grew its stake in Atossa Therapeutics by 4.2% in the third quarter. State Street Corp now owns 1,732,221 shares of the company's stock valued at $2,633,000 after purchasing an additional 69,180 shares in the last quarter. XTX Topco Ltd increased its position in Atossa Therapeutics by 101.2% in the 3rd quarter. XTX Topco Ltd now owns 49,616 shares of the company's stock worth $75,000 after purchasing an additional 24,951 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Atossa Therapeutics by 1.6% during the 3rd quarter. Geode Capital Management LLC now owns 2,814,446 shares of the company's stock worth $4,278,000 after purchasing an additional 44,762 shares in the last quarter. Finally, The Manufacturers Life Insurance Company acquired a new stake in shares of Atossa Therapeutics during the 3rd quarter valued at about $75,000. Hedge funds and other institutional investors own 12.74% of the company's stock.

Atossa Therapeutics Company Profile

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.